Vi uppgraderar Mina sidor under maj
Boka, videobesök och chatt fungerar som vanligt i HLTHY medan vi bygger nästa version av Mina sidor.
Medical guide
Retatrutide is a new triple agonist (GLP-1, GIP, glucagon) showing promising weight-loss results, but it is not yet approved.
minutes reading time
10 min
Updated
15 January 2026
Reviewed by
Dr. Dorél Lehrer
Content
Rx education
Dr. Dorél Lehrer
Licensed Physician
Retatrutide targets three receptors and has shown strong weight-loss outcomes in trials. It remains investigational in many markets.
Licensed Physician
Medicinskt granskad: 15 January 2026
This article is educational and does not replace individual care. Which medicine may be relevant is decided by a licensed doctor after medical assessment. Prescription issuing is included only when a doctor decides it is medically appropriate.
Medicinskt granskad av Dr. Dorél Lehrer, 15 January 2026. Innehållsrisk: rx-education.
Retatrutide is an investigational medication designed to target three metabolic pathways and may deliver substantial weight loss.
By activating GLP-1, GIP, and glucagon receptors, retatrutide aims to improve appetite regulation and energy balance.
The medication is still under clinical investigation and is not yet broadly approved.
Denna artikel är medicinsk information skriven av Dr. Dorél Lehrer, Licensed Physician. Eventuell behandling sker efter individuell bedömning av legitimerad läkare.
Related Articles
'/%3e%3c/g%3e%3c/svg%3e)
